Export

ATC codes: H02AB02
EMLc
Indication
Lymphoid leukaemia, NOS ICD11 code: 2C03.3
INN
Dexamethasone
Medicine type
Chemical agent
List type
Complementary
Formulations
Oral > Liquid: 2 mg per 5 mL (EMLc)
Oral > Solid: 2 mg (EMLc) ; 4 mg
Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
EML status history
First added in 1977 (TRS 615)
Changed in 2015 (TRS 994)
Sex
All
Age
Also recommended for children
Therapeutic equivalence
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Tags
Wikipedia
Summary of evidence and Expert Committee recommendations
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for asparaginase on the complementary list of the EML and EMLc for use in treatment protocols for acute lymphoblastic leukaemia (ALL) was recommended. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for ALL is attached.